SCHEMBL2155481

SCHEMBL2155481

O=S(=O)(/C=C/C#Cc1ccccc1)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
LMNA P02545 2/20 0.64
MEN1 O00255 1/20 0.64
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 3/20 0.46
GAA P10253 2/20 0.46
GPR183 P32249 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
USP30 Q70CQ3 1/20 0.40
HSD11B1 P28845 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155489 1.00 KMT2A (0.64) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2156829 1.00 KMT2A (0.64) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2155808 0.89 TSHR (0.51) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2155803 0.89 TSHR (0.51) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2155375 0.88 TSHR (0.50) KMT2ALMNAMEN1ALDH1A1TSHR
SCHEMBL2155373 0.88 TSHR (0.50) KMT2ALMNAMEN1ALDH1A1TSHR
SCHEMBL2156787 0.87 MEN1 (0.48) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2156781 0.87 MEN1 (0.48) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2155444 0.87 LMNA (0.51) KMT2ALMNAMEN1ALDH1A1HPGD
SCHEMBL2155435 0.87 LMNA (0.51) KMT2ALMNAMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP claimed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US claimed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US claimed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 CN claimed
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS KMT2A 3464/4885LMNA 3423/4885MEN1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.